secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001171843-26-000273
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system
--------------------------------------------------------------------------------

- Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.
- Procedure uses AI-powered, directional ultrasound from inside urethra to heat tissue to 55-57°C while protecting nerves; no blood loss or overnight stay.
- Patient discharged same day; initial treatment outcome positive.
- Profound CEO Arun Menawat noted collaboration between Urology and Interventional Radiology at Mount Sinai.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/0001171843-26-000273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326000273/f8k_011526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer